Novel methods to SCREEN, DETECT and PROTECT against life threatening RESPIRATORY DYSFUNCTION
| Reference number | |
| Coordinator | SAMSARA MEDICIN AKTIEBOLAG |
| Funding from Vinnova | SEK 450 000 |
| Project duration | November 2012 - January 2014 |
| Status | Completed |
Important results from the project
The overall goal of the project is to establish a novel diagnostic application to monitor patients at risk of developing life threatening breathing disorders such as severe apnea, including sleep apnea and viral pneumonitis. This is achieved by exploiting the use of the prostaglandin pathway in the screening, diagnosis and treatment of respiratory dysfunction.
Expected long term effects
We have established new methods and an assay to detect a stable non-degraded metabolite of PGE2, directly related to serum levels that is secreted into urine. Urine is readily available and can routinely be sampled.
Approach and implementation
The subject matter in the project is being preserved in a patent application (WO2009/063226). Current status: National phase in USA, EU and Canada. China and Japan has not been prioritized. First examination from EPO is done and response has been submitted. USA has also examined the application. Initial handling of the IPR was done with KIAB. In 2010 KIAB declined further collaboration for strategic reasons. KI also declined adminstrative handling of the IPR. The inventors transferred IPR to the company Samsara Medicin AB for practical reasons.